Key result
CXCL16 triggers shear-dependent platelet activation and adhesion via CXCR6, blunted by PI3K inhibitors and cangrelor.
Answers are grounded in this paper and cite their sources.
RATIONALE: The recently discovered chemokine CXC motif ligand 16 (CXCL16) is highly expressed in atherosclerotic lesions and is a potential pathogenic mediator in coronary artery disease. OBJECTIVE: The aim of this study was to test the role of CXCL16 on platelet activation and vascular adhesion, as well as the underlying mechanism and signaling pathway. METHODS AND RESULTS: Reverse-transcriptase polymerase chain reaction, Western blotting, confocal microscopy, and flow cytometry revealed that CXCL16-specific receptor, CXC motif receptor 6, is highly expressed in platelets. According to flow cytometry and confocal microscopy, stimulation of platelets with CXCL16 induced platelet degranulation, integrin α(IIb)β(3) activation, and shape change. CXCL16 increased Akt phosphorylation (Thr(308)/Ser(473)), an effect abrogated by phosphatidylinositide 3-kinase inhibitors wortmannin (100 nmol/L) and LY294002 (25 µmol/L). The phosphatidylinositide 3-kinase inhibitors and Akt inhibitor SH-6 (20 µmol/L) further diminished CXCL16-induced platelet activation. CXCL16-mediated platelet degranulation, integrin α(IIb)β(3) activation, and Akt phosphorylation were blunted in platelets lacking CXCL16-specific receptor CXC motif receptor 6. CXCL16-induced platelet activation was abrogated in Akt1- or Akt2-deficient platelets. CXCL16 enhanced platelet adhesion to endothelium in vitro after high arterial shear stress (2000(-s)) and to injured vascular wall in vivo after carotid ligation. CXCL16-induced stimulation of platelet adhesion again was prevented by phosphatidylinositide 3-kinase and Akt inhibitors. Apyrase and antagonists of platelet purinergic receptors P(2)Y(1) (MRS2179, 100 µmol/L) and especially P(2)Y(12) (Cangrelor, 10 µmol/L) blunted CXCL16-triggered platelet activation as well as CXCL16-induced platelet adhesion under high arterial shear stress in vitro and after carotid ligation in vivo. CONCLUSIONS: The inflammatory chemokine CXCL16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling and paracrine activation, suggesting a decisive role for CXCL16 in linking vascular inflammation and thrombo-occlusive diseases.
No takes yet. Share an insight, caveat, or question.
Borst et al. (2012) studied Platelet activation and thrombo-occlusive diseases. CXC motif ligand 16 (CXCL16) vs. PI3K/Akt inhibitors (wortmannin 100 nmol/L, LY294002 25 µmol/L, SH-6 20 µmol/L), P2Y1/P2Y12 antagonists (MRS2179 100 µmol/L, Cangrelor 10 µmol/L), and CXCR6/Akt1/Akt2 deficiency was evaluated on Platelet activation (degranulation, integrin αIIbβ3 activation, shape change) and vascular adhesion. CXCL16 stimulation triggered CXCR6-dependent platelet activation and adhesion at 2000(-s) shear stress, which was abrogated by wortmannin (100 nmol/L), LY294002 (25 µmol/L), and cangrelor (10 µmol/L).
Synapse has enriched 10 related papers. Consider them for comparative context: